kabutan

Solasia Pharma K.K.(4597) Summary

4597
TSE Growth
Solasia Pharma K.K.
34
JPY
+1
(+3.03%)
Apr 28, 3:30 pm JST
0.21
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
33.9
Apr 30, 8:56 am JST
Summary Chart Historical News Financial Result
PER
PBR
5.30
Yield
ー%
Margin Trading Ratio
2.75
Stock Price
Apr 28, 2026
Opening Apr 28, 9:00 am
33 JPY 0.20 USD
Previous Close Apr 27
33 JPY 0.20 USD
High Apr 28, 10:43 am
35 JPY 0.22 USD
Low Apr 28, 9:00 am
33 JPY 0.20 USD
Volume
51,701,000
Trading Value
1.73B JPY 0.01B USD
VWAP
33.51 JPY 0.21 USD
Minimum Trading Value
3,400 JPY 21 USD
Market Cap
9.30B JPY 0.06B USD
Number of Trades
171
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
Mid
1-Year Average
321
1-Year High Jun 27, 2025
2,772
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 2,938,900 16,951,800 5.77
Apr 17, 2026 5,046,100 20,933,400 4.15
Apr 10, 2026 1,802,800 19,053,600 10.57
Apr 3, 2026 1,337,900 19,837,600 14.83
Mar 27, 2026 988,000 20,318,500 20.57
Company Profile
Solasia Pharma K.K. is a biopharmaceutical venture company focused on cancer and malignant tumor drug discovery. The company engages in the development of pharmaceuticals and medical devices, with a primary focus on clinical development.
Sector
Pharmaceuticals
Solasia Pharma K.K. operates as a biopharmaceutical venture company specializing in the oncology field, developing both pharmaceuticals and medical devices. The company primarily concentrates on clinical development, introducing promising new drug candidates and conducting trials in Japan and other Asian countries. With multiple development pipelines, Solasia focuses on treatments for malignant tumors and supportive care medications. Their product portfolio includes darinaparsin for peripheral T-cell lymphoma, a transdermal granisetron preparation for preventing chemotherapy-induced nausea and vomiting, and a medical device aimed at alleviating pain from oral mucositis. The company's business model encompasses the entire process from clinical development to regulatory submission and out-licensing of marketing rights. Solasia aims to generate revenue through out-licensing to pharmaceutical companies, which includes sales revenue, milestone payments, and royalty income.